Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: Martin Wormser who wrote (340)	7/11/1998 2:20:00 AM
From: David Lawrence	Respond to of 384

Free enterprise and the American way.

To: Martin Wormser who wrote (340)	7/11/1998 7:44:00 AM
From: Tenpoint	Respond to of 384

"Was it greed" On the part of who? The Brand companies or Mylan? The pre-game show has just started. Milan Puskar refused to take his bonus of $500,000.00 in fiscal 1997 even though the criteria was met. Just FYI.

To: Martin Wormser who wrote (340)	7/11/1998 9:07:00 PM
From: Druggist	Read Replies (2) \| Respond to of 384

Well, from my limited knowledge, it was 1) raw material cornering, shortage, whatever... 2) generic industry very competitive, and they are just sick and tired of watching name brand companies set their high prices and they stick, they are now doing the same.. remember... these are not ALL generic prices, just a picking of some.. In Mylans case, 7 drugs... Besides Mylan, I have witnessed price increases (over 25%) on - Purepak - Geneva Generics - Rugby so I think we will more and more of this... the play would be to invest in drug wholesalers (cardinal, mckesson, etc...) and the individual stocks... One IPO I bought into 2 months back was Schein.. they opened at 21 and have hit 32... that is my next buy... I am holding Mylan October 35 calls now that I bought for $ 2.00.. Druggist hope this helps !!